Nagesh Palepu

Nagesh Palepu

, BS, PhD



Nagesh Palepu is a seasoned professional in pharmaceutical development, with a career spanning over 30 years working in big pharma, generics, and drug delivery companies. After obtaining his MSc in Chemistry from the esteemed India Institute of Technology (IIT), Bombay in 1972, he immigrated to the United States and began his career at Pfizer in pharmaceutical research and development. After five years as a bench chemist, Dr. Palepu began his PhD studies in pharmaceutics at the University of Iowa. Upon graduation, he joined Bristol Myers (now BMS) as a research scientist primarily focused on anticancer drugs. He was a critical member of the team responsible for filing the New Drug Applications (NDAs) for carboplatin and injectable cephalosporin and the supplemental NDAs (sNDAs) for Platinol AQ and Mutamycin. In 1983, Dr. Palepu left Bristol Myers and joined Adria Laboratories in Columbus, Ohio as a section head of formulation development (though his sports loyalty remained with the Iowa Hawkeyes). At Adria, he successfully filed ten ANDAs (abbreviated new drug applications), the NDA for Zinecard, and the sNDA for Adriamycin RTU (ready-to-use). Dr. Palepu left Adria after five years and joined SmithKline Beecham (now GSK) where he oversaw development of three NDAs (Topotecan, Teveten, and Avandia). After 25 years working in global pharmaceutical giants, he joined Geneva Pharmaceuticals as vice president of Research & Development, where he was heavily involved in planning and executing strategic steps to grow Geneva (now Sandoz) into a major global generics player. An opportunity at an oncology-focused drug delivery company, Sonus Pharmaceuticals, relocated Dr. Palepu from Colorado to Seattle, Washington.

With 29 years working in various sectors of the pharmaceutical industry under his belt, Dr. Palepu ventured out on his own and simultaneously founded a pharmaceutical consultancy and a research and development company in Hyderabad, India. He met future business partner Joseph Bohan during a consulting assignment, and they founded SciDose LLC in early 2006. Since its inception, SciDose has obtained FDA approval on two products and is awaiting approval on three more. The self-funded company focuses primarily on anti-cancer products, reformulating existing compounds in the short-term, and developing novel compounds in the long-term.

Over his career, Dr. Palepu has published over 25 journal articles and has filed over 50 US patents as inventor/co-inventor.


He received his doctorate in pharmaceutics from the University of Iowa in 1984.